Indivior PLC
Update in progressINDV (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Indivior Pharmaceuticals, Inc., including its subsidiaries, develops, manufactures, and sells buprenorphine-based medicines for opioid dependence and related disorders in the United States, Europe, Canada, Australia, and beyond. Key products include SUBLOCADE (buprenorphine extended-release monthly), SUBOXONE Film (buprenorphine/naloxone sublingual), SUBOXONE Tablet, and SUBUTEX Tablet. It is developing INDV-2000 (orexin-1 antagonist) in Phase 2 and INDV-6001 (buprenorphine long-acting injectable) with Alar Pharmaceuticals. Formerly Indivior PLC, renamed Indivior Pharmaceuticals, Inc. in January 2026. Incorporated 2014, based in North Chesterfield, Virginia.
Company score
- Sentiment
- -0.03
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.03
- Governance
- -0.38
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.09
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.06
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Loading section